Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535483 | 1.00 | LMNA (0.33) | LMNANPSR1CHRM1 | |
| SCHEMBL17535554 | 0.89 | NPSR1 (0.34) | LMNANPSR1CHRM1 | |
| SCHEMBL17535556 | 0.89 | NPSR1 (0.34) | LMNANPSR1CHRM1 | |
| SCHEMBL16875246 | 0.82 | NPSR1 (0.43) | LMNANPSR1CHRM1 | |
| SCHEMBL1537011 | 0.82 | NPSR1 (0.43) | LMNANPSR1CHRM1 | |
| SCHEMBL16942019 | 0.80 | NPSR1 (0.36) | LMNANPSR1CHRM1 | |
| SCHEMBL21404238 | 0.77 | NPSR1 (0.43) | LMNANPSR1CHRM1 | |
| SCHEMBL9959207 | 0.76 | NPSR1 (0.43) | LMNANPSR1CHRM1 | |
| SCHEMBL22027027 | 0.76 | NPSR1 (0.37) | LMNANPSR1CHRM1 | |
| SCHEMBL1536077 | 0.74 | NPSR1 (0.38) | LMNANPSR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | LMNA 4589/4885NPSR1 19/4885CHRM1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.